Skip to search formSkip to main contentSkip to account menu

Residual Tumor

Known as: Residual Disease, Tumors, Residual, Residual Tumors 
Cancer cells that remain after attempts to remove the cancer have been made.
National Institutes of Health

Related topics

Related topics

4 relations
Malignant NeoplasmsNeoplasm, ResidualResidual Cancercancer risk

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?
Highly Cited
2003
Highly Cited
2003
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
INTRODUCTION Response to neoadjuvant chemotherapy for locally advanced breast cancer can be correlated with long-term outcomes… 
Highly Cited
1999
Highly Cited
1999
Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced?
Highly Cited
1999
Highly Cited
1999
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
PURPOSE Concurrent biochemotherapy results in high response rates but also significant toxicity in patients with metastatic… 
Highly Cited
1996
Highly Cited
1996
ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
To study acute myelogenous leukemia 1 (AML1) transcription factor, ETO protein, and t(8;21) AML chimeric AML1/ ETO protein in… 
Highly Cited
1995
Highly Cited
1995
Overexpression of c‐erbB‐2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy
Background. Overexpression of the c‐erbB‐2 protein has been reported in tumors from approximately 25% of patients with epithelial… 
Highly Cited
1994
Highly Cited
1994
Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia.
Determining both lymphoid chimerism and the presence of minimal residual disease after allogeneic bone marrow transplantation… 
Highly Cited
1993
Highly Cited
1993
Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome.
Highly Cited
1989
Highly Cited
1989
Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen.
A series of 71 patients with muscle invasive bladder cancer received a median of 3 cycles (range 1-6) of methotrexate… 
Highly Cited
1976
Highly Cited
1976
The role of repeat transurethral biopsy in stage A carcinoma of the prostate.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)